JPRN-UMIN000012100已完成1 期
A feasible study of lenalidomide for multiple myeloma in maintenance use at post autologous peripheral blood stem cell transplantation - Lenalidomide maintenance therapy in patients with multiple myeloma
Ochanomizu blood study committee0 个研究点目标入组 15 人开始时间: 2013年10月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Known hypersensitivity to lenalidomide (2) Peripheral neuropathy or neuropathic pain grade 2 or higher as defined by NCI CTCAE version 2 (3) Uncontroled infectious diseases (4) HBs antigen, HCV antibody positive (5) HTLV-I antibody, HCV antibody positive (6) Pregnancy or breastfeeding (7) Active ulcer detected by gastroscopy (gastroscopy is not routine in all patients, only to patients with symptoms of ulcer disease and/or history of previous ulcer therapy and/or physician's discretion)
研究者
相似试验
进行中（未招募）
不适用
Feasibility and efficacy of Lenalidomide maintenance after salvage immuno-chemotherapy induction in relapsed or refractory mantle cell lymphoma - a phase II study of the European MCL Networkpatients with relapsed or refractory mantle cell lymphoma after or not eligible for myeloablative treatmentMedDRA version: 12.0Level: PTClassification code 10026800Term: Mantle cell lymphoma recurrentMedDRA version: 12.0Level: PTClassification code 10026801Term: Mantle cell lymphoma refractoryEUCTR2008-000678-19-DEKlinikum der Universität München, Klinikum Großhadern60
终止
2 期
Lenalidomide Maintenance Therapy for Multiple MyelomaMultiple MyelomaNCT01675141National Cancer Institute (NCI)11
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line TherapyB-cell Chronic Lymphocytic LeukemiaNCT00774345Celgene317
已完成
3 期
A Study of the Effect of Lenalidamide on Complex Regional Pain Syndrome Type 1Complex Regional Pain Syndrome, Type 1NCT00166452Mayo Clinic7
Unknown
1 期
Third-line Therapy of Multiple Myeloma a Prospective Phase I /II TrialMultiple MyelomaNCT01010243University of Regensburg54